Table 2.
SIRs for overall and lung cancers reported in the literature in epidemiological studies of patients with RA
| Cohort information | SIR | 95% CI | |
|---|---|---|---|
| All cancers | |||
| Thomas (females)43 | DMARD | 0.97 | 0.92 to 1.02 |
| Thomas (males)43 | DMARD | 1.10 | 1.02 to 1.18 |
| Ekstrom44 | NS | 1.07 | 1.05 to 1.09 |
| Wolfe1 | Non-biological and/or biological DMARDs | 1.0 | 1.0 to 1.1 |
| Abásolo45 | DMARDS, corticosteroids | 1.2 | 0.8 to 1.8 |
| Hemminki8 | NS | 1.23 | 1.19 to 1.27 |
| Simon6 | Meta-analysis* | 1.09 | 10.6 to 1.13 |
| Lung cancer | |||
| Thomas (females)43 | DMARDs | 1.44 | 1.27 to 1.62 |
| Thomas (males)43 | DMARDs | 1.32 | 1.15 to 1.51 |
| Askling3 | NS | 1.48 | 1.33 to 1.65 |
| aTNF | 1.8 | 0.9 to 3.3 | |
| Setoguchi7 | Non-biological and/or biological DMARDs | 1.80 | 1.52 to 2.05 |
| Wolfe1 | Non-biological and/or biological DMARDs | 1.2 | 1.0 to 1.4 |
| Abásolo45 | DMARDS, corticosteroids | 3.5 | 1.4 to 7.1 |
| Hemminki8 | NS | 1.73 | 1.57 to 1.89 |
| Simon6 | Meta-analysis* | 1.64 | 1.51 to 1.79 |
*Meta analysis included data from epidemiological studies listed above.
aTNF, antitumour necrosis factor; DMARD, disease-modifying antirheumatic drug; NS; not specified; RA, rheumatoid arthritis; SIR, standardised incidence ratio.